Fig. 2

CD45-specific PTP inhibitor relieves the oxidative stress in aged MSCs. A Representative flow cytometry panel depicts the percentage of DCF + cells in young, aged, and aged MSCs after PTP inhibitor treatment. B Graphical representation shows mean fluorescence intensity (MFI) of DCF + cells in young, aged, and PTP inhibitor-treated aged MSCs. Data show a significant reduction in ROS levels in the aged MSCs after PTP inhibitor treatment. C (C a–b) qRT-PCR analyses for Nrf1- and Nrf2-specific mRNAs in young, aged, and PTP inhibitor-treated aged MSCs. Data represent the relative expression of transcripts normalized relative to GAPDH and expressed as the Mean ± SEM for three biologically independent experiments (n = 3). One-way ANOVA followed by Bonferroni post hoc test in Graph pad prism 6 version 6.0 (GraphPad Software Inc, La Jolla, CA) was used. All the data are represented as mean ± SD. *p < 0.05; **p < 0.01; ***p < 0.001, ****p < 0.0001; ns not significant. D Immunofluorescence staining of young (a), aged MSCs (b), and PTP inhibitor-treated aged MSCs (c) with an antibody against NF-κβ protein. E MFI of NF-kB signal was measured in 10 cells. Nuclear and cytoplasmic signals were calculated from at least 5 non-overlapping fields for each group using ImageJ software (n = 7). Nuclei vs. cytoplasm ratio of NF-κB signals is graphically represented. Scale bar 10 μm (×63 magnification). All the data are represented as mean ± SD. *p < 0.05; **p < 0.01; ***p < 0.001, ****p < 0.0001; ns not significant. MSCs mesenchymal stem cells, PTP protein tyrosine phosphatase, MFI mean fluorescence intensity